Palisade Bio (NASDAQ:PALI) Announces Quarterly Earnings Results

Palisade Bio (NASDAQ:PALI) posted its earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01), FiscalAI reports.

Palisade Bio Stock Performance

Shares of NASDAQ PALI traded up $0.02 during trading on Wednesday, reaching $1.94. The stock had a trading volume of 353,422 shares, compared to its average volume of 4,250,427. Palisade Bio has a fifty-two week low of $0.53 and a fifty-two week high of $2.86. The business’s 50-day moving average price is $1.98 and its 200-day moving average price is $1.92. The company has a market cap of $323.96 million, a P/E ratio of -0.91 and a beta of 1.52.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a report on Thursday, January 22nd. Wolfe Research started coverage on Palisade Bio in a research report on Thursday, April 9th. They issued an “outperform” rating and a $7.00 target price on the stock. Stifel Nicolaus started coverage on Palisade Bio in a research note on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target on the stock. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Finally, HC Wainwright assumed coverage on shares of Palisade Bio in a report on Thursday, March 26th. They issued a “buy” rating and a $7.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $10.20.

Hedge Funds Weigh In On Palisade Bio

Hedge funds have recently bought and sold shares of the company. XTX Topco Ltd grew its position in Palisade Bio by 53.8% in the 4th quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock valued at $51,000 after acquiring an additional 7,584 shares in the last quarter. Cetera Investment Advisers acquired a new stake in shares of Palisade Bio during the fourth quarter worth about $25,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Palisade Bio during the fourth quarter worth about $26,000. Virtu Financial LLC purchased a new position in shares of Palisade Bio in the fourth quarter valued at approximately $28,000. Finally, Atom Investors LP acquired a new position in shares of Palisade Bio in the fourth quarter valued at approximately $33,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

Palisade Bio Company Profile

Palisade Bio, Inc is a clinical?stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll?like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.